Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 2.67% is 74% below its 2-year average of 10.19%, near the low end of its 2-year range (2.67%–20.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 63.27% below its 12-month average of 7.27%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.67%.
DEBT TO ASSETS RATIO
2.67%
DEBT TO ASSETS RATIO AVG TTM
7.27%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-63.27%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 539 covered companies
CURRENT VS SECTOR MEDIAN
+2571.76%
vs the sector median at left
Artiva Biotherapeutics, Inc.
Market Cap
$341.86M
Debt to Assets Ratio
2.67%
TTM Avg
7.27%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$344.13M
Debt to Assets Ratio
0.74%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$336.71M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$329.60M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$361.64M
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$363.70M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $341.86M | 2.67% | 7.27% | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $344.13M | 0.74% | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $345.29M | 1.19% | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $336.71M | 0.10% | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $352.29M | 0.24% | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $329.60M | 0.16% | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $323.01M | 0.04% | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | 0.38% | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $363.70M | 0.00% | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $365.95M | 0.19% | N/A | N/A | N/A |
Debt/Assets
2.7%
Debt/Equity
0.03
Current Ratio
24.16
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 2.67% |
| 2026-03-31 | 9.69% |
| 2025-12-31 | 8.36% |
| 2025-09-30 | 7.85% |
| 2025-06-30 | 7.81% |
| 2025-03-31 | 7.32% |
| 2024-12-31 | 6.85% |
| 2024-09-30 | 6.63% |
| 2024-06-30 | 20.77% |
| 2024-03-31 | 18.03% |
| 2023-12-31 | 16.09% |
